• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

renal denervation

Medtronic’s renal denervation system demonstrates better blood pressure control, time in range

May 17, 2022 By Sean Whooley

Medtronic (NYSE:MDT) announced today that new data supports the use of its Symplicity Spyral renal denervation (RDN) system. As part of the medtech giant’s Spyral HTN global clinical program, three-year data from the Spyral HTN-ON MED and GSR-Define trials were presented at EuroPCR 2022 as late-breaking clinical trials demonstrating the benefit of the Symplicity blood […]

Filed Under: Blood Management, Cardiovascular, Clinical Trials, Featured, News Well Tagged With: Medtronic, renal denervation

Medtronic releases new renal denervation results, closes trial enrollment

April 4, 2022 By Jim Hammerand

Medtronic (NYSE:MDT) today said its Symplicity Spyral renal denervation (RDN) system demonstrated durable, clinically significant blood pressure reductions through three years for patients on medication. It’s the latest development out of Medtronic’s Spyral HTN-ON MED trial testing the company’s RDN catheter system, which delivers radiofrequency energy to overactive nerves near the kidneys that cause high blood pressure. […]

Filed Under: Blog, Cardiovascular, Catheters, Clinical Trials, Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: FDA, Hypertension, Medtronic, renal denervation

Some analysts are upbeat about Medtronic’s renal denervation prospects

March 21, 2022 By Chris Newmarker

Needham & Co. analysts are reiterating their Buy rating for Medtronic stock, saying that renal denervation (RDN) could still be a big opportunity for the medtech giant. Medtronic (NYSE:MDT) had to continue its Spyral HTN-ON MED trial into this year after failing to obtain the positive results needed to end enrollment early for the potential […]

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Featured, News Well, Research & Development, Wall Street Beat Tagged With: Medtronic, renal denervation

MedtronicTalks: Why Symplicity Spyral trials are complicated, but worth it

December 2, 2021 By Tom Salemi

Medtronic’s campaign to secure FDA approval of its renal denervation device — Symplicity Spyral — has been anything but simple. But in this episode of the MedtronicTalks podcast, Jason Weidman, SVP and president of Coronary & Renal Denervation, explains why the company has refused to give up the fight to develop the renal denervation tool […]

Filed Under: Cardiovascular, Catheters, Device Talks Podcasts, Featured Tagged With: Hypertension, Medtronic, renal denervation

Medtronic builds suspense for renal denervation study results

September 10, 2021 By Jim Hammerand

Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference. The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar […]

Filed Under: Clinical Trials, Research & Development Tagged With: Hypertension, Medtronic, renal denervation

Is renal denervation back as a high blood pressure treatment?

May 18, 2021 By Chris Newmarker

Medtronic (NYSE:MDT) today reported clinically significant and sustained blood pressure reduction among nearly 3,000 people with uncontrolled hypertension treated with the company’s Symplicity renal denervation system. The study results, reported today out of the 2021 EuroPCR Annual Meeting, come the same week as ReCor Medical touted its own positive renal denervation study at the American […]

Filed Under: Cardiovascular, Featured, Neurological, Research & Development Tagged With: Medtronic, ReCor Medical, renal denervation

ReCor Medical has positive renal denervation study news

May 17, 2021 By Chris Newmarker

ReCor Medical‘s renal denervation significantly reduced blood pressure among people with drug-resistant hypertension, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session. The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry, […]

Filed Under: Cardiovascular, Catheters, Featured, Neuromodulation/Neurostimulation Tagged With: ACC 2021, Medtronic, ReCor Medical, renal denervation

Medtronic to test new ways to fine-tune renal denervation

February 7, 2020 By Chris Newmarker

As it continues to seek a renaissance in renal denervation, Medtronic (NYSE:MDT) plans to study how to better fine-tune the technology to treat hypertension. The world’s largest medical device company, run out of Fridley, Minn., announced Feb. 4 that it has started enrollment in a pilot study that will use the company’s Symplicity Spyral renal denervation […]

Filed Under: Clinical Trials, Featured, Vascular Tagged With: Medtronic, renal denervation

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS